Healthcare technology and technology assessment
| Autor: | James H, Herndon, Raymond, Hwang, K J, Bozic, K H, Bozic |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
medicine.medical_specialty
Technology Assessment Biomedical Transparency (market) Emerging technologies Cost-Benefit Analysis Consumer choice Biomedical Technology Technology assessment Health care Humans Medicine Medical physics Orthopedic Procedures Orthopedics and Sports Medicine Marketing Biomedical technology health care economics and organizations Equipment Safety United States Food and Drug Administration business.industry Health technology Health Care Costs Health Care Technology Private sector Spine United States Editorial Surgery Erratum business |
| Zdroj: | European Spine Journal. 16:1293-1302 |
| ISSN: | 1432-0932 0940-6719 |
| DOI: | 10.1007/s00586-007-0369-z |
| Popis: | New technology is one of the primary drivers for increased healthcare costs in the United States. Both physician and industry play important roles in the development, adoption, utilization and choice of new technologies. The Federal Drug Administration regulates new drugs and new medical devices, but healthcare technology assessment remains limited. Healthcare technology assessment originated in federal agencies; today it is decentralized with increasing private sector efforts. Innovation is left to free market forces, including direct to consumer marketing and consumer choice. But to be fair to the consumer, he/she must have free knowledge of all the risks and benefits of a new technology in order to make an informed choice. Physicians, institutions and industry need to work together by providing proven, safe, clinically effective and cost effective new technologies, which require valid pre-market clinical trials and post-market continued surveillance with national and international registries allowing full transparency of new products to the consumer--the patient. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink